Physician profile
Deepak Karibassappa
NPI 1770776627
$1,386.14
in general payments reported to CMS, 2019-2025
20 companies · $13.87 in 2025
The $13.87 reported for 2025 was less than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $907 · 2020: $202 · 2021: $153 · 2022: $17.89 · 2023: $91.77 · 2025: $13.87.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $105.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $235.98 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $216.98 | 2019-2021 | |
| Pfizer INC. | $201.37 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $145.23 | 2019-2021 | |
| Chiesi USA, INC. | $91.77 | 2023 | Cleviprex |
| E.R. Squibb & Sons, L.L.C. | $62.57 | 2019 | |
| Allergan, INC. | $56.31 | 2019 | |
| Alexion Pharmaceuticals, INC. | $47.63 | 2019 | |
| Mylan Specialty L.P. | $44.20 | 2019 | |
| Shire North American Group INC | $41.18 | 2019 | |
| Paratek Pharmaceuticals, INC. | $37.64 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.12 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $34.08 | 2020-2025 | Lifevest |
| Vapotherm INC | $32.13 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $28.67 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nuwellis, INC. | $16.80 | 2020 | |
| Abbvie INC. | $15.12 | 2021 | |
| Portola Pharmaceuticals, LLC | $14.02 | 2019 | |
| Janssen Biotech, INC. | $13.72 | 2020 | |
| Merck Sharp & Dohme LLC | $13.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepak Karibassappa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.